DK
Do Kim Piper Sandler Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$9.76B
| $61.23 | $63 |
3%
upside
| Overweight |
22 Feb ‘24
1 year ago |
|
2
Travere Therapeutics
TVTX
$1.93B
| $21.64 | $46 |
113%
upside
| Overweight |
21 Feb ‘23
2 years ago |
|
3
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $296 |
25%
downside
| Neutral |
8 Feb ‘23
2 years ago |
|
4
Gilead Sciences
GILD
$143B
| $115.05 | $112 |
3%
downside
| Overweight |
3 Feb ‘23
2 years ago |
|
5
Schrodinger
SDGR
$1.41B
| $19.13 | $87 |
355%
upside
| Overweight |
19 Jan ‘23
2 years ago |
|
6
Codexis
CDXS
$218M
| $2.42 | $23 |
850%
upside
| Overweight |
19 Jan ‘23
2 years ago |
|
7
Rigel Pharmaceuticals
RIGL
$742M
| $41.34 | $20 |
52%
downside
| Neutral |
17 Aug ‘22
3 years ago |
|
8
Replimune Group
REPL
$494M
| $6.33 | $43 |
579%
upside
| Overweight |
16 Aug ‘22
3 years ago |
|
9
Exelixis
EXEL
$10.2B
| $37.88 | $32 |
16%
downside
| Overweight |
26 Jul ‘22
3 years ago |
|
10
AbCellera Biologics
ABCL
$1.26B
| $4.22 | $22 |
421%
upside
| Overweight |
26 Jul ‘22
3 years ago |
|
11
Scholar Rock
SRRK
$3.02B
| $31.41 | $19 |
40%
downside
| Overweight |
23 Jun ‘22
3 years ago |
|
|
12
Ionis Pharmaceuticals
IONS
$9.76B
| $61.23 | $76 |
24%
upside
| Outperform |
23 Mar ‘21
4 years ago |
|
13
Nuvation Bio
NUVB
$1.33B
| $3.90 | $16 |
310%
upside
| Outperform |
8 Mar ‘21
4 years ago |
|
|
14
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $284 |
28%
downside
| Outperform |
2 Feb ‘21
4 years ago |
|
15
Alnylam Pharmaceuticals
ALNY
$59.2B
| $452 | $185 |
59%
downside
| Market Perform |
25 Jan ‘21
4 years ago |
|
|
16
AbCellera Biologics
ABCL
$1.26B
| $4.22 | $48 |
1,037%
upside
| Outperform |
5 Jan ‘21
4 years ago |
|
17
Exicure
XCUR
$30M
| $4.75 | $900 |
18,847%
upside
| Outperform |
18 Dec ‘20
4 years ago |
|
|
18
Travere Therapeutics
TVTX
$1.93B
| $21.64 | $33 |
53%
upside
| Outperform |
6 Nov ‘20
4 years ago |
|
|
19
Schrodinger
SDGR
$1.41B
| $19.13 | $67 |
250%
upside
| Outperform |
14 May ‘20
5 years ago |
|
20
Halozyme
HALO
$8.76B
| $74.93 | $35 |
53%
downside
| Outperform |
12 May ‘20
5 years ago |
|